Search Results for “FDA” – Page 186 – media

China’s Import and Export Market of Obstetrics and Gynecology Equipment

Development of technology over the past couple of decades has led to societal and cultural development which in turn has resulted in awareness of issues such as the importance of women’s health. With vast improvements taking place in this field, obstetrics and gynecology equipment has experienced major changes.
- Source: Ddu
- 1,276
- September 20, 2017
export gynecology import Market Reports obstetrics
Centinel Spine acquires Prodisc assets from J&J’s DePuy Synthes

Centinel Spine has agreed to acquire Johnson & Johnson (NYSE:JNJ) subsidiary DePuy Synthes’ Prodisc assets for an undisclosed amount, according to an OrthoWorld report.
- Source: Massdevice
- 662
- September 20, 2017
acquisition Market Views Prodisc
Checkpoint Therapeutics Receives Orphan Drug Designation for CK-101 for the Treatment of EGFR Mutation-Positive Non-Small Cell Lung Cancer

The U.S. Food and Drug Administration (FDA) has granted Checkpoint Therapeutics, Inc. (“Checkpoint”) (CKPT)'s Orphan Drug Designation to CK-101 (also known as RX518), the Company’s third-generation epidermal growth-factor receptor (EGFR) inhibitor, for the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC).
- Source: finance.yahoo
- 499
- September 12, 2017
FDA inhibitor NSCLC
Regeneron (REGN) And Sanofi (SNY) Announce Positive Dupilumab Topline Results From Phase III Trial In Uncontrolled Persistent Asthma

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the pivotal Phase 3 LIBERTY ASTHMA QUEST study of dupilumab in a broad population of patients with uncontrolled, persistent asthma met its two primary endpoints.
- Source: careers.biospace
- 552
- September 12, 2017
asthma Clinical Trials dupilumab Phase
Verastem’s Duvelisib Succeeds in Late-Stage Blood Cancer Study

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today reported positive top-line results from the Phase 3 DUO study evaluating the efficacy and safety of duvelisib, a first in class oral dual inhibitor of phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma, in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
- Source: Spjnews
- 739
- September 8, 2017
cancer Clinical Trials CLL inhibitor SLL
MicroPort Orthopedics launches new acetabular cup system

MicroPort Orthopedics has launched its new Procotyl Prime Acetabular Cup System, following 510(k) clearance from the US Food and Drug Administration in June.
- Source: medicaldevice-network
- 468
- August 31, 2017
acetabular cup system Company Insight MicroPort Orthopedics
US OKs first drug for dyskinaesia in Parkinson’s patients

US regulators have approved the first and only treatment option to treat dyskinaesia in patients with Parkinson's disease.
- Source: pharmatimes
- 696
- August 28, 2017
dyskinaesia New Approvals Parkinson
Cel-Sci raises $3.5m for head and neck cancer immunotherapy

Cel-Sci said today that for a Phase III trial of its investigational immunotherapy, it inked an agreement with institutional investors for a $3.5 million registered direct offering.
- Source: drugdeliverybusiness
- 523
- August 24, 2017
Clinical Trials Company Insight immunotherapy
J&J’s Ethicon launches ProxiSure laparoscopic suturing device

The ProxiSure laparoscopic suturing device was launched, said Johnson & Johnson (NYSE:JNJ) subsidiary Ethicon.
- Source: massdevice
- 517
- August 22, 2017
Company Insight FDA laparoscopic suturing
US regulators wave through Pfizer’s leukaemia drug

Pfizer’s Besponsa has been approved by the US Food and Drug Administration (FDA). It's the first and only CD22-directed antibody-drug conjugate indicated to treat relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL).
- Source: pharmatimes
- 1,029
- August 21, 2017
ALL antibody Company Insight FDA New Approvals

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.